Ardent Health, Inc. — Form 8-K
Filed August 4, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 42/100
What the filing says
Ardent Health reported Q2 2026 net income of $17M ($0.12/share) vs. $73M ($0.52/share) YoY; total revenue declined 1.4% to $1.62B; Adjusted EBITDA fell 32.3% to $115M. Admissions decreased 1.0% and surgeries fell 2.9%, largely due to prior-year comparison with two quarters of New Mexico directed payment benefits. The company reaffirmed full-year 2026 guidance: revenue $6.4–$6.7B and Adjusted EBITDA $485–$535M, citing improved payor contracts and increased IMPACT cost-savings target (now $70M vs. $55M). Operating cash flow surged 67% YoY to $197M; the company repurchased 1.4M shares for $13M and has $34M remaining in authorization.
Why this rating
Q2 earnings collapse (76% YoY decline in net income) is material to guidance reset and operational execution concerns, but reaffirmed guidance and strong cash flow partially offset. Relative to $324M market cap, the $55M EBITDA miss (~10% of guidance midpoint) is meaningful. New CEO transition adds execution risk.
See more from August 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.